Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
02/14/2017 02/15/2017 02/16/2017 02/17/2017 02/20/2017 Date
237.4(c) 241.5(c) 242.8(c) 243.5(c) 244(c) Last
2 465 879 2 374 101 2 711 536 2 961 580 1 510 119 Volume
-1.08% +1.73% +0.54% +0.29% +0.21% Change
More quotes
Financials ( CHF)
Sales 2017 53 242 M
EBIT 2017 18 326 M
Net income 2017 11 736 M
Debt 2017 9 381 M
Yield 2017 3,56%
Sales 2018 56 030 M
EBIT 2018 19 749 M
Net income 2018 12 819 M
Debt 2018 3 349 M
Yield 2018 3,80%
P/E ratio 2017 17,94
P/E ratio 2018 16,63
EV / Sales2017 4,15x
EV / Sales2018 3,83x
Capitalization 211 512 M
More Financials
Company
Roche Holding AG operates as a research healthcare company.It operates through the following segments: Diagnostics and Pharmaceuticals.The pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience.The... 
Sector
Pharmaceuticals
Calendar
02/27Presentation
More about the company
Surperformance© ratings of Roche Holding Ltd.
Trading Rating : Investor Rating :
More Ratings
Latest news on ROCHE HOLDING LTD.
06:29p ROCHE : Global Histology Equipment Market- Leica, Roche, Sakura Finetek, Thermo ..
03:55p CHUGAI PHARMACEUTICAL : New Drug Application Filed for Immune Checkpoint Inhibit..
10:04a ROCHE : Phase II study supports potential for Roche's TECENTRIQ (atezolizumab) p..
02/19 ROCHE : College basketball
02/18 ROCHE : Phase II study supports potential for Roche’s TECENTRIQ (atezolizu..
02/18 ROCHE : Phase II Study Supports Potential for Genentech’s Tecentriq® (Atez..
02/17DJROCHE : U.S. Obtains Records in Lobbyist Probe -- WSJ
02/17DJROCHE : FBI Searches for Possible Accomplices in Probe of Fallen K Street Lobbyi..
02/16 ROCHE : Federal Contracts Awarded by Federal Agencies in Louisiana (Feb. 16)
02/16 ROCHE : $188,290 Federal Contract Awarded to Roche Diagnostics
More news
Sector news : Pharmaceuticals - NEC
08:45p Collapse of Kraft-Unilever tie-up extends run of failed mega-deals
01:23pDJBAYER : Trump Backing for Bayer's Monsanto Deal Buoys Investors
01:06pDJBAYER : 4Q 2016 -- Forecast
08:25aDJASTRAZENECA : licenses Cancer Drug Zoladex to TerSera for the US, Canada
02/17DJSHIRE : Files 8K - Other Events
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on ROCHE HOLDING LTD. 
2016An opportunity over the medium term?
2016A medium term support level to take advantage of
More Strategies
Latest Tweets
02/19Vincent Roche, CEO of ADI, & his daughter at AAAS . Pictured here w/ Hari..
2
02/19Roche Holding Ltd. $RHHBY Receives “Buy” Rating from Jefferies Group LLC  
02/19Roche Holding's buy rating reiterated at Jefferies Group LLC.  
02/18Min. @Paschald reviews Austerity and Recovery in Ireland, edited by Roche, @a..
1
02/18Roche says Phase II trial supports twin treatment for kidney cancer: Yahoo/Re.. 
More tweets
Qtime:98
News from SeekingAlpha
02/17 What Makes Amgen A Compelling Buy In 2017?
02/17 Take The Road Less Traveled
02/16 Verubecestat Halt Fails To Stop The Bace Chase
02/16 Genentech fighting to delay looming market entry of Amgen's Avastin biosimila..
02/15 BioLineRx - Undervalued With Significant Pipeline, Large Pharma Collaboration..
Advertisement
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Full-screen chart
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 279  CHF
Spread / Average Target 15%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.4.69%210 814
JOHNSON & JOHNSON3.17%323 362
PFIZER INC.3.51%204 018
NOVARTIS AG3.91%202 998
MERCK & CO., INC.11.08%180 289
SANOFI5.97%111 739
More Results